You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDasatinib
Accession NumberDB01254
TypeSmall Molecule
GroupsApproved, Investigational
Description

Dasatinib is an oral dual BCR/ABL and Src family tyrosine kinase inhibitor approved for use in patients with chronic myelogenous leukemia (CML). The main targets of Dasatinib, are BCRABL, SRC, Ephrins and GFR.

Structure
Thumb
Synonyms
anh. dasatinib
Anhydrous dasatinib
BMS dasatinib
Dasatinib
Dasatinib (anh.)
dasatinib (anhydrous)
Dasatinibum
N-(2-CHLORO-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide
External Identifiers
  • BMS-354825
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Spryceltablet70 mg/1oralE.R. Squibb & Sons, L.L.C.2006-06-27Not applicableUs
Spryceltablet70 mg/1oralPhysicians Total Care, Inc.2007-02-12Not applicableUs
Spryceltablet140 mgoralBristol Myers Squibb Canada2011-03-29Not applicableCanada
Spryceltablet140 mg/1oralE.R. Squibb & Sons, L.L.C.2010-10-28Not applicableUs
Spryceltablet80 mgoralBristol Myers Squibb Canada2011-09-02Not applicableCanada
Spryceltablet80 mg/1oralE.R. Squibb & Sons, L.L.C.2010-10-28Not applicableUs
Spryceltablet100 mgoralBristol Myers Squibb Canada2009-05-04Not applicableCanada
Spryceltablet100 mg/1oralE.R. Squibb & Sons, L.L.C.2008-05-30Not applicableUs
Spryceltablet70 mgoralBristol Myers Squibb Canada2007-04-13Not applicableCanada
Spryceltablet50 mg/1oralE.R. Squibb & Sons, L.L.C.2006-06-27Not applicableUs
Spryceltablet50 mgoralBristol Myers Squibb Canada2007-04-13Not applicableCanada
Spryceltablet20 mg/1oralE.R. Squibb & Sons, L.L.C.2006-06-27Not applicableUs
Spryceltablet20 mgoralBristol Myers Squibb Canada2007-04-13Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Dasatinib monohydrate
863127-77-9
Thumb
  • InChI Key: XHXFZZNHDVTMLI-UHFFFAOYSA-N
  • Monoisotopic Mass: 505.1662867
  • Average Mass: 506.02
DBSALT001849
Categories
UNIIX78UG0A0RN
CAS number302962-49-8
WeightAverage: 488.006
Monoisotopic: 487.155721508
Chemical FormulaC22H26ClN7O2S
InChI KeyInChIKey=ZBNZXTGUTAYRHI-UHFFFAOYSA-N
InChI
InChI=1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)
IUPAC Name
N-(2-chloro-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide
SMILES
CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as n-arylpiperazines. These are organic compounds containing a piperazine ring where the nitrogen ring atom carries an aryl group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassDiazinanes
Sub ClassPiperazines
Direct ParentN-arylpiperazines
Alternative Parents
Substituents
  • N-arylpiperazine
  • N-arylamide
  • Aminotoluene
  • Dialkylarylamine
  • Thiazolecarboxylic acid or derivatives
  • Thiazolecarboxamide
  • N-alkylpiperazine
  • Toluene
  • Halobenzene
  • Chlorobenzene
  • Aminopyrimidine
  • 2,5-disubstituted 1,3-thiazole
  • Imidolactam
  • Benzenoid
  • Pyrimidine
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl chloride
  • Heteroaromatic compound
  • Thiazole
  • Azole
  • Tertiary aliphatic amine
  • Tertiary amine
  • Secondary carboxylic acid amide
  • Carboxamide group
  • 1,2-aminoalcohol
  • Azacycle
  • Secondary amine
  • Carboxylic acid derivative
  • Alkanolamine
  • Hydrocarbon derivative
  • Primary alcohol
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia with resistance or intolerance to prior therapy. Also indicated for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy.
PharmacodynamicsDasatinib is an oral dual BCR/ABL and Src family tyrosine kinase inhibitor
Mechanism of actionDasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRβ. Based on modeling studies, dasatinib is predicted to bind to multiple conformations of the ABL kinase. In vitro, dasatinib was active in leukemic cell lines representing variants of imatinib mesylate sensitive and resistant disease. Dasatinib inhibited the growth of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) cell lines overexpressing BCR-ABL. Under the conditions of the assays, dasatinib was able to overcome imatinib resistance resulting from BCR-ABL kinase domain mutations, activation of alternate signaling pathways involving the SRC family kinases (LYN, HCK), and multi-drug resistance gene overexpression.
Related Articles
AbsorptionNot Available
Volume of distribution
  • 2505 L
Protein binding96%
Metabolism

Dasatinib is extensively metabolized in humans, primarily by the cytochrome P450 enzyme 3A4

Route of eliminationDasatinib is extensively metabolized in humans, primarily by the cytochrome P450 enzyme 3A4. Elimination is primarily via the feces.
Half lifeThe overall mean terminal half-life of dasatinib is 3-5 hours.
ClearanceNot Available
ToxicityAcute overdose in animals was associated with cardiotoxicity.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9852
Blood Brain Barrier-0.507
Caco-2 permeable-0.5638
P-glycoprotein substrateSubstrate0.6562
P-glycoprotein inhibitor IInhibitor0.5371
P-glycoprotein inhibitor IIInhibitor0.5425
Renal organic cation transporterNon-inhibitor0.7288
CYP450 2C9 substrateNon-substrate0.7061
CYP450 2D6 substrateNon-substrate0.8152
CYP450 3A4 substrateSubstrate0.5704
CYP450 1A2 substrateNon-inhibitor0.5612
CYP450 2C9 inhibitorInhibitor0.8008
CYP450 2D6 inhibitorNon-inhibitor0.8358
CYP450 2C19 inhibitorInhibitor0.574
CYP450 3A4 inhibitorInhibitor0.7295
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8343
Ames testNon AMES toxic0.7185
CarcinogenicityNon-carcinogens0.7308
BiodegradationNot ready biodegradable0.9863
Rat acute toxicity2.4772 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8538
hERG inhibition (predictor II)Inhibitor0.718
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Tabletoral100 mg/1
Tabletoral100 mg
Tabletoral140 mg/1
Tabletoral140 mg
Tabletoral20 mg
Tabletoral20 mg/1
Tabletoral50 mg
Tabletoral50 mg/1
Tabletoral70 mg/1
Tabletoral70 mg
Tabletoral80 mg
Tabletoral80 mg/1
Prices
Unit descriptionCostUnit
Sprycel 100 mg tablet278.24USD tablet
Sprycel 50 mg tablet139.12USD tablet
Sprycel 70 mg tablet139.12USD tablet
Sprycel 20 mg tablet69.56USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2366932 No2009-08-252020-04-12Canada
US6596746 No2000-06-282020-06-28Us
US7125875 No2000-04-132020-04-13Us
US7153856 No2000-04-282020-04-28Us
US7491725 No2006-03-282026-03-28Us
US8680103 No2005-02-042025-02-04Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point280-286 °CNot Available
logP1.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0128 mg/mLALOGPS
logP2.77ALOGPS
logP3.82ChemAxon
logS-4.6ALOGPS
pKa (Strongest Acidic)8.49ChemAxon
pKa (Strongest Basic)7.22ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area106.51 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity133.08 m3·mol-1ChemAxon
Polarizability51.58 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceUS6596746
General References
  1. Das J, Chen P, Norris D, Padmanabha R, Lin J, Moquin RV, Shen Z, Cook LS, Doweyko AM, Pitt S, Pang S, Shen DR, Fang Q, de Fex HF, McIntyre KW, Shuster DJ, Gillooly KM, Behnia K, Schieven GL, Wityak J, Barrish JC: 2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor. J Med Chem. 2006 Nov 16;49(23):6819-32. [PubMed:17154512 ]
  2. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O'Brien S, Nicaise C, Bleickardt E, Blackwood-Chirchir MA, Iyer V, Chen TT, Huang F, Decillis AP, Sawyers CL: Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006 Jun 15;354(24):2531-41. [PubMed:16775234 ]
External Links
ATC CodesL01XE06
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (237 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
AbciximabDasatinib may increase the anticoagulant activities of Abciximab.
AbirateroneThe serum concentration of Abiraterone can be increased when it is combined with Dasatinib.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Dasatinib.
AcenocoumarolDasatinib may increase the anticoagulant activities of Acenocoumarol.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Dasatinib.
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Dasatinib.
Acetylsalicylic acidDasatinib may increase the anticoagulant activities of Acetylsalicylic acid.
AdinazolamThe serum concentration of Adinazolam can be increased when it is combined with Dasatinib.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Dasatinib.
AlbendazoleThe serum concentration of Albendazole can be increased when it is combined with Dasatinib.
AlclometasoneThe serum concentration of Alclometasone can be increased when it is combined with Dasatinib.
AldosteroneThe serum concentration of Dasatinib can be decreased when it is combined with Aldosterone.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Dasatinib.
AlectinibThe serum concentration of Dasatinib can be increased when it is combined with Alectinib.
AlfentanilThe serum concentration of Alfentanil can be increased when it is combined with Dasatinib.
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Dasatinib.
AliskirenThe serum concentration of Aliskiren can be increased when it is combined with Dasatinib.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Dasatinib.
AllylestrenolThe serum concentration of Allylestrenol can be increased when it is combined with Dasatinib.
AlmotriptanThe serum concentration of Almotriptan can be increased when it is combined with Dasatinib.
AlogliptinThe serum concentration of Alogliptin can be increased when it is combined with Dasatinib.
AlosetronThe serum concentration of Alosetron can be increased when it is combined with Dasatinib.
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Dasatinib.
AlprostadilDasatinib may increase the anticoagulant activities of Alprostadil.
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aluminum phosphateAluminum phosphate can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
AmantadineThe serum concentration of Dasatinib can be increased when it is combined with Amantadine.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Dasatinib.
AmbroxolThe serum concentration of Ambroxol can be increased when it is combined with Dasatinib.
Aminohippuric acidThe serum concentration of Dasatinib can be increased when it is combined with Aminohippuric acid.
AminophenazoneThe serum concentration of Aminophenazone can be increased when it is combined with Dasatinib.
AminophyllineThe serum concentration of Aminophylline can be increased when it is combined with Dasatinib.
AmiodaroneThe serum concentration of Amiodarone can be increased when it is combined with Dasatinib.
AmiodaroneThe serum concentration of Dasatinib can be decreased when it is combined with Amiodarone.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Dasatinib.
AmlodipineThe serum concentration of Amlodipine can be increased when it is combined with Dasatinib.
AmprenavirThe serum concentration of Amprenavir can be increased when it is combined with Dasatinib.
AmprenavirThe serum concentration of Dasatinib can be decreased when it is combined with Amprenavir.
AmsacrineThe serum concentration of Dasatinib can be increased when it is combined with Amsacrine.
AnagrelideDasatinib may increase the anticoagulant activities of Anagrelide.
AncrodDasatinib may increase the anticoagulant activities of Ancrod.
AntipyrineThe serum concentration of Antipyrine can be increased when it is combined with Dasatinib.
Antithrombin III humanDasatinib may increase the anticoagulant activities of Antithrombin III human.
ApixabanDasatinib may increase the anticoagulant activities of Apixaban.
ApremilastThe serum concentration of Apremilast can be increased when it is combined with Dasatinib.
AprepitantThe serum concentration of Dasatinib can be increased when it is combined with Aprepitant.
ArdeparinDasatinib may increase the anticoagulant activities of Ardeparin.
ArgatrobanDasatinib may increase the anticoagulant activities of Argatroban.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Dasatinib.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Dasatinib.
ArtemetherThe serum concentration of Artemether can be increased when it is combined with Dasatinib.
AsenapineThe serum concentration of Asenapine can be increased when it is combined with Dasatinib.
AsenapineAsenapine can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
AstemizoleThe serum concentration of Astemizole can be increased when it is combined with Dasatinib.
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Dasatinib.
AtenololThe serum concentration of Dasatinib can be increased when it is combined with Atenolol.
AtomoxetineThe metabolism of Dasatinib can be decreased when combined with Atomoxetine.
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Dasatinib.
AvanafilThe serum concentration of Avanafil can be increased when it is combined with Dasatinib.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Dasatinib.
AzelastineDasatinib may increase the anticoagulant activities of Azelastine.
AzelastineThe serum concentration of Dasatinib can be increased when it is combined with Azelastine.
AzithromycinThe serum concentration of Azithromycin can be increased when it is combined with Dasatinib.
BanoxantroneThe serum concentration of Banoxantrone can be increased when it is combined with Dasatinib.
BecaplerminDasatinib may increase the anticoagulant activities of Becaplermin.
BedaquilineThe serum concentration of Bedaquiline can be increased when it is combined with Dasatinib.
BenzocaineThe serum concentration of Dasatinib can be increased when it is combined with Benzocaine.
BenzphetamineThe serum concentration of Benzphetamine can be increased when it is combined with Dasatinib.
Benzyl alcoholThe serum concentration of Benzyl alcohol can be increased when it is combined with Dasatinib.
BepridilThe serum concentration of Dasatinib can be increased when it is combined with Bepridil.
BeraprostDasatinib may increase the anticoagulant activities of Beraprost.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Dasatinib.
BevacizumabBevacizumab may increase the cardiotoxic activities of Dasatinib.
BexaroteneThe serum concentration of Bexarotene can be increased when it is combined with Dasatinib.
BexaroteneThe serum concentration of Dasatinib can be decreased when it is combined with Bexarotene.
BezafibrateThe serum concentration of Bezafibrate can be increased when it is combined with Dasatinib.
BicalutamideThe serum concentration of Bicalutamide can be increased when it is combined with Dasatinib.
BiperidenThe serum concentration of Dasatinib can be increased when it is combined with Biperiden.
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
BisoprololThe serum concentration of Bisoprolol can be increased when it is combined with Dasatinib.
BivalirudinDasatinib may increase the anticoagulant activities of Bivalirudin.
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Dasatinib.
BortezomibThe serum concentration of Bortezomib can be increased when it is combined with Dasatinib.
BortezomibThe metabolism of Dasatinib can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Bosentan can be increased when it is combined with Dasatinib.
BosentanThe serum concentration of Dasatinib can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Dasatinib.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Dasatinib.
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Dasatinib.
BrinzolamideThe serum concentration of Brinzolamide can be increased when it is combined with Dasatinib.
BromazepamThe serum concentration of Bromazepam can be increased when it is combined with Dasatinib.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Dasatinib.
BrompheniramineThe serum concentration of Brompheniramine can be increased when it is combined with Dasatinib.
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Dasatinib.
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Dasatinib.
BuprenorphineThe serum concentration of Buprenorphine can be increased when it is combined with Dasatinib.
BupropionThe serum concentration of Bupropion can be increased when it is combined with Dasatinib.
BuspironeThe serum concentration of Buspirone can be increased when it is combined with Dasatinib.
BusulfanThe serum concentration of Busulfan can be increased when it is combined with Dasatinib.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Dasatinib.
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Dasatinib.
CabozantinibThe serum concentration of Cabozantinib can be increased when it is combined with Dasatinib.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Dasatinib.
CalcitriolThe serum concentration of Calcitriol can be increased when it is combined with Dasatinib.
Calcium carbonateCalcium carbonate can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Dasatinib.
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Dasatinib.
CandesartanThe serum concentration of Dasatinib can be increased when it is combined with Candesartan.
CangrelorDasatinib may increase the anticoagulant activities of Cangrelor.
CaptoprilThe serum concentration of Dasatinib can be increased when it is combined with Captopril.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Dasatinib.
CarbamazepineThe serum concentration of Dasatinib can be decreased when it is combined with Carbamazepine.
CarbinoxamineThe serum concentration of Carbinoxamine can be increased when it is combined with Dasatinib.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Dasatinib.
CariprazineThe serum concentration of Cariprazine can be increased when it is combined with Dasatinib.
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Dasatinib.
CaspofunginThe serum concentration of Dasatinib can be increased when it is combined with Caspofungin.
CelecoxibThe serum concentration of Celecoxib can be increased when it is combined with Dasatinib.
CeliprololThe serum concentration of Celiprolol can be increased when it is combined with Dasatinib.
CephalexinThe serum concentration of Cephalexin can be increased when it is combined with Dasatinib.
CeritinibThe serum concentration of Dasatinib can be increased when it is combined with Ceritinib.
CeritinibDasatinib may increase the QTc-prolonging activities of Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Dasatinib.
CertoparinDasatinib may increase the anticoagulant activities of Certoparin.
CevimelineThe serum concentration of Cevimeline can be increased when it is combined with Dasatinib.
Chenodeoxycholic acidThe serum concentration of Chenodeoxycholic acid can be increased when it is combined with Dasatinib.
ChlordiazepoxideThe serum concentration of Chlordiazepoxide can be increased when it is combined with Dasatinib.
ChloroquineThe serum concentration of Chloroquine can be increased when it is combined with Dasatinib.
ChlorphenamineThe serum concentration of Chlorphenamine can be increased when it is combined with Dasatinib.
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Dasatinib.
ChlorpropamideThe serum concentration of Dasatinib can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe serum concentration of Dasatinib can be increased when it is combined with Chlorprothixene.
ChlorzoxazoneThe serum concentration of Chlorzoxazone can be increased when it is combined with Dasatinib.
CholecalciferolThe serum concentration of Cholecalciferol can be increased when it is combined with Dasatinib.
CholesterolThe serum concentration of Dasatinib can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Dasatinib can be decreased when it is combined with Cholic Acid.
CiclesonideThe serum concentration of Ciclesonide can be increased when it is combined with Dasatinib.
CilazaprilThe serum concentration of Dasatinib can be increased when it is combined with Cilazapril.
CilostazolDasatinib may increase the anticoagulant activities of Cilostazol.
CimetidineCimetidine can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Dasatinib.
CinacalcetThe serum concentration of Cinacalcet can be increased when it is combined with Dasatinib.
CiprofloxacinDasatinib may increase the QTc-prolonging activities of Ciprofloxacin.
CiprofloxacinThe serum concentration of Dasatinib can be increased when it is combined with Ciprofloxacin.
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Dasatinib.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Dasatinib.
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Dasatinib.
Citric AcidDasatinib may increase the anticoagulant activities of Citric Acid.
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Dasatinib.
ClemastineThe metabolism of Dasatinib can be decreased when combined with Clemastine.
ClindamycinThe serum concentration of Clindamycin can be increased when it is combined with Dasatinib.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Dasatinib.
ClofazimineThe serum concentration of Clofazimine can be increased when it is combined with Dasatinib.
ClofibrateThe serum concentration of Clofibrate can be increased when it is combined with Dasatinib.
clomethiazoleThe serum concentration of clomethiazole can be increased when it is combined with Dasatinib.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Dasatinib.
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Dasatinib.
ClonazepamThe serum concentration of Clonazepam can be increased when it is combined with Dasatinib.
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Dasatinib.
ClopidogrelDasatinib may increase the anticoagulant activities of Clopidogrel.
ClorazepateThe serum concentration of Clorazepate can be increased when it is combined with Dasatinib.
ClotiazepamThe serum concentration of Clotiazepam can be increased when it is combined with Dasatinib.
ClotrimazoleThe metabolism of Dasatinib can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Dasatinib is combined with Clozapine.
CobicistatThe serum concentration of Dasatinib can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Dasatinib.
CocaineThe serum concentration of Cocaine can be increased when it is combined with Dasatinib.
CodeineThe serum concentration of Codeine can be increased when it is combined with Dasatinib.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Dasatinib.
ColforsinThe serum concentration of Dasatinib can be increased when it is combined with Colforsin.
ConivaptanThe serum concentration of Dasatinib can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Dasatinib.
Cortisone acetateThe serum concentration of Cortisone acetate can be increased when it is combined with Dasatinib.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Dasatinib.
CrizotinibThe metabolism of Dasatinib can be decreased when combined with Crizotinib.
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Dasatinib.
CyclophosphamideThe serum concentration of Cyclophosphamide can be increased when it is combined with Dasatinib.
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Dasatinib.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Dasatinib.
CyclosporineThe metabolism of Dasatinib can be decreased when combined with Cyclosporine.
Cyproterone acetateThe serum concentration of Dasatinib can be decreased when it is combined with Cyproterone acetate.
CytarabineThe serum concentration of Cytarabine can be increased when it is combined with Dasatinib.
Dabigatran etexilateDasatinib may increase the anticoagulant activities of Dabigatran etexilate.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Dasatinib.
DabrafenibThe serum concentration of Dasatinib can be decreased when it is combined with Dabrafenib.
DaclatasvirThe serum concentration of Daclatasvir can be increased when it is combined with Dasatinib.
DactinomycinThe serum concentration of Dasatinib can be increased when it is combined with Dactinomycin.
DalteparinDasatinib may increase the anticoagulant activities of Dalteparin.
DanaparoidDasatinib may increase the anticoagulant activities of Danaparoid.
DantroleneThe serum concentration of Dantrolene can be increased when it is combined with Dasatinib.
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Dasatinib.
DapsoneThe serum concentration of Dapsone can be increased when it is combined with Dasatinib.
DarifenacinThe serum concentration of Darifenacin can be increased when it is combined with Dasatinib.
DarunavirThe serum concentration of Darunavir can be increased when it is combined with Dasatinib.
DasabuvirThe serum concentration of Dasabuvir can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Dasatinib can be decreased when it is combined with Daunorubicin.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Dasatinib can be decreased when it is combined with Deferasirox.
DefibrotideDasatinib may increase the anticoagulant activities of Defibrotide.
DehydroepiandrosteroneThe serum concentration of Dehydroepiandrosterone can be increased when it is combined with Dasatinib.
DelavirdineThe serum concentration of Delavirdine can be increased when it is combined with Dasatinib.
DelavirdineThe metabolism of Dasatinib can be decreased when combined with Delavirdine.
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Dasatinib.
DesipramineThe serum concentration of Dasatinib can be increased when it is combined with Desipramine.
DesirudinDasatinib may increase the anticoagulant activities of Desirudin.
DeslanosideDeslanoside may decrease the cardiotoxic activities of Dasatinib.
DesloratadineThe serum concentration of Dasatinib can be increased when it is combined with Desloratadine.
DesvenlafaxineThe serum concentration of Desvenlafaxine can be increased when it is combined with Dasatinib.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Dasatinib.
DexamethasoneThe serum concentration of Dasatinib can be decreased when it is combined with Dexamethasone.
DextranDasatinib may increase the anticoagulant activities of Dextran.
Dextran 40Dasatinib may increase the anticoagulant activities of Dextran 40.
Dextran 70Dasatinib may increase the anticoagulant activities of Dextran 70.
Dextran 75Dasatinib may increase the anticoagulant activities of Dextran 75.
DextromethorphanThe serum concentration of Dextromethorphan can be increased when it is combined with Dasatinib.
DextropropoxypheneThe serum concentration of Dextropropoxyphene can be increased when it is combined with Dasatinib.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Dasatinib.
DiclofenacThe serum concentration of Diclofenac can be increased when it is combined with Dasatinib.
DicoumarolDasatinib may increase the anticoagulant activities of Dicoumarol.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Dasatinib.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Dasatinib.
DigitoxinDigitoxin may decrease the cardiotoxic activities of Dasatinib.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Dasatinib.
DigoxinDigoxin may decrease the cardiotoxic activities of Dasatinib.
DihydrocodeineThe serum concentration of Dihydrocodeine can be increased when it is combined with Dasatinib.
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Dasatinib.
DihydroergotamineThe metabolism of Dasatinib can be decreased when combined with Dihydroergotamine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Dasatinib.
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Dasatinib.
DiltiazemThe metabolism of Dasatinib can be decreased when combined with Diltiazem.
DipyridamoleDasatinib may increase the anticoagulant activities of Dipyridamole.
DipyridamoleThe serum concentration of Dasatinib can be increased when it is combined with Dipyridamole.
DisopyramideThe serum concentration of Disopyramide can be increased when it is combined with Dasatinib.
DisulfiramThe serum concentration of Disulfiram can be increased when it is combined with Dasatinib.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Dasatinib.
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Dasatinib.
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Dasatinib.
DolasetronThe serum concentration of Dolasetron can be increased when it is combined with Dasatinib.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Dasatinib.
DonepezilThe serum concentration of Donepezil can be increased when it is combined with Dasatinib.
DorzolamideThe serum concentration of Dorzolamide can be increased when it is combined with Dasatinib.
DoxazosinThe serum concentration of Dasatinib can be increased when it is combined with Doxazosin.
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Dasatinib.
DoxepinDoxepin can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
DoxorubicinThe serum concentration of Dasatinib can be decreased when it is combined with Doxorubicin.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Dasatinib.
DoxycyclineThe metabolism of Dasatinib can be decreased when combined with Doxycycline.
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Dasatinib.
DronedaroneThe serum concentration of Dronedarone can be increased when it is combined with Dasatinib.
DronedaroneThe metabolism of Dasatinib can be decreased when combined with Dronedarone.
DroperidolDasatinib may increase the QTc-prolonging activities of Droperidol.
DutasterideThe serum concentration of Dutasteride can be increased when it is combined with Dasatinib.
Edetic AcidDasatinib may increase the anticoagulant activities of Edetic Acid.
EdoxabanDasatinib may increase the anticoagulant activities of Edoxaban.
EfavirenzThe serum concentration of Efavirenz can be increased when it is combined with Dasatinib.
EfavirenzThe serum concentration of Dasatinib can be decreased when it is combined with Efavirenz.
ElbasvirThe serum concentration of Dasatinib can be increased when it is combined with Elbasvir.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Dasatinib.
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Dasatinib.
EltrombopagThe serum concentration of Dasatinib can be increased when it is combined with Eltrombopag.
ElvitegravirThe serum concentration of Elvitegravir can be increased when it is combined with Dasatinib.
EnalaprilThe serum concentration of Enalapril can be increased when it is combined with Dasatinib.
EnoxaparinDasatinib may increase the anticoagulant activities of Enoxaparin.
EnzalutamideThe serum concentration of Enzalutamide can be increased when it is combined with Dasatinib.
EpinastineDasatinib may increase the anticoagulant activities of Epinastine.
EpinastineEpinastine can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
EplerenoneThe serum concentration of Eplerenone can be increased when it is combined with Dasatinib.
EpoprostenolDasatinib may increase the anticoagulant activities of Epoprostenol.
EptifibatideDasatinib may increase the anticoagulant activities of Eptifibatide.
ErgocalciferolThe serum concentration of Ergocalciferol can be increased when it is combined with Dasatinib.
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Dasatinib.
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Dasatinib.
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Dasatinib.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Dasatinib.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Dasatinib.
ErythromycinThe metabolism of Dasatinib can be decreased when combined with Erythromycin.
EscitalopramThe serum concentration of Escitalopram can be increased when it is combined with Dasatinib.
Eslicarbazepine acetateThe serum concentration of Dasatinib can be decreased when it is combined with Eslicarbazepine acetate.
EsomeprazoleThe serum concentration of Esomeprazole can be increased when it is combined with Dasatinib.
EsomeprazoleThe serum concentration of Dasatinib can be decreased when it is combined with Esomeprazole.
EstazolamThe serum concentration of Estazolam can be increased when it is combined with Dasatinib.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Dasatinib.
Estradiol valerate/DienogestThe serum concentration of Estradiol valerate/Dienogest can be increased when it is combined with Dasatinib.
EstramustineThe serum concentration of Estramustine can be increased when it is combined with Dasatinib.
EstriolThe serum concentration of Dasatinib can be decreased when it is combined with Estriol.
EstriolThe serum concentration of Estriol can be increased when it is combined with Dasatinib.
EstroneThe serum concentration of Estrone can be increased when it is combined with Dasatinib.
EstroneThe serum concentration of Dasatinib can be decreased when it is combined with Estrone.
Estrone sulfateThe serum concentration of Estrone sulfate can be increased when it is combined with Dasatinib.
EszopicloneThe serum concentration of Eszopiclone can be increased when it is combined with Dasatinib.
EthanolThe serum concentration of Ethanol can be increased when it is combined with Dasatinib.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Dasatinib.
EthosuximideThe serum concentration of Ethosuximide can be increased when it is combined with Dasatinib.
Ethyl biscoumacetateDasatinib may increase the anticoagulant activities of Ethyl biscoumacetate.
EthylmorphineThe serum concentration of Ethylmorphine can be increased when it is combined with Dasatinib.
EtonogestrelThe serum concentration of Etonogestrel can be increased when it is combined with Dasatinib.
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Dasatinib.
EtoricoxibThe serum concentration of Etoricoxib can be increased when it is combined with Dasatinib.
EtravirineThe serum concentration of Etravirine can be increased when it is combined with Dasatinib.
EtravirineThe serum concentration of Dasatinib can be decreased when it is combined with Etravirine.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Dasatinib.
ExemestaneThe serum concentration of Exemestane can be increased when it is combined with Dasatinib.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Dasatinib.
FamciclovirThe serum concentration of Famciclovir can be increased when it is combined with Dasatinib.
FamotidineFamotidine can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
FelbamateThe serum concentration of Felbamate can be increased when it is combined with Dasatinib.
FelodipineThe serum concentration of Felodipine can be increased when it is combined with Dasatinib.
FenofibrateThe serum concentration of Fenofibrate can be increased when it is combined with Dasatinib.
FentanylThe serum concentration of Fentanyl can be increased when it is combined with Dasatinib.
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Dasatinib.
FexofenadineThe serum concentration of Dasatinib can be increased when it is combined with Fexofenadine.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Dasatinib.
FinasterideThe serum concentration of Finasteride can be increased when it is combined with Dasatinib.
FingolimodThe serum concentration of Fingolimod can be increased when it is combined with Dasatinib.
FlecainideDasatinib may increase the QTc-prolonging activities of Flecainide.
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Dasatinib.
FluconazoleThe metabolism of Dasatinib can be decreased when combined with Fluconazole.
FlunisolideThe serum concentration of Flunisolide can be increased when it is combined with Dasatinib.
FlunitrazepamThe serum concentration of Flunitrazepam can be increased when it is combined with Dasatinib.
FluorometholoneThe serum concentration of Fluorometholone can be increased when it is combined with Dasatinib.
FluoxetineThe serum concentration of Fluoxetine can be increased when it is combined with Dasatinib.
FlupentixolThe serum concentration of Dasatinib can be increased when it is combined with Flupentixol.
FlupentixolDasatinib may increase the QTc-prolonging activities of Flupentixol.
FluphenazineThe serum concentration of Dasatinib can be increased when it is combined with Fluphenazine.
FlurazepamThe serum concentration of Flurazepam can be increased when it is combined with Dasatinib.
FlutamideThe serum concentration of Flutamide can be increased when it is combined with Dasatinib.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Dasatinib.
Fluticasone PropionateThe serum concentration of Fluticasone Propionate can be increased when it is combined with Dasatinib.
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Dasatinib.
FluvoxamineThe metabolism of Dasatinib can be decreased when combined with Fluvoxamine.
Fondaparinux sodiumDasatinib may increase the anticoagulant activities of Fondaparinux sodium.
FosamprenavirThe serum concentration of Fosamprenavir can be increased when it is combined with Dasatinib.
FosamprenavirThe metabolism of Dasatinib can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Dasatinib can be increased when it is combined with Fosaprepitant.
FosphenytoinThe serum concentration of Dasatinib can be decreased when it is combined with Fosphenytoin.
FulvestrantThe serum concentration of Fulvestrant can be increased when it is combined with Dasatinib.
Fusidic AcidThe serum concentration of Dasatinib can be increased when it is combined with Fusidic Acid.
Gadobenic acidDasatinib may increase the QTc-prolonging activities of Gadobenic acid.
GalantamineThe serum concentration of Galantamine can be increased when it is combined with Dasatinib.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Dasatinib.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Dasatinib.
GemfibrozilThe serum concentration of Gemfibrozil can be increased when it is combined with Dasatinib.
GemifloxacinDasatinib may increase the QTc-prolonging activities of Gemifloxacin.
GenisteinThe serum concentration of Dasatinib can be increased when it is combined with Genistein.
GlipizideThe serum concentration of Glipizide can be increased when it is combined with Dasatinib.
GlyburideThe serum concentration of Glyburide can be increased when it is combined with Dasatinib.
GlycerolThe serum concentration of Dasatinib can be increased when it is combined with Glycerol.
GoserelinDasatinib may increase the QTc-prolonging activities of Goserelin.
Gramicidin DThe serum concentration of Dasatinib can be increased when it is combined with Gramicidin D.
GranisetronThe serum concentration of Granisetron can be increased when it is combined with Dasatinib.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Dasatinib.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Dasatinib.
GuanfacineThe serum concentration of Guanfacine can be increased when it is combined with Dasatinib.
HalofantrineThe serum concentration of Halofantrine can be increased when it is combined with Dasatinib.
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Dasatinib.
HalothaneThe serum concentration of Halothane can be increased when it is combined with Dasatinib.
HeparinDasatinib may increase the anticoagulant activities of Heparin.
HexobarbitalThe serum concentration of Hexobarbital can be increased when it is combined with Dasatinib.
HirulogDasatinib may increase the anticoagulant activities of Hirulog.
Histamine PhosphateThe serum concentration of Histamine Phosphate can be increased when it is combined with Dasatinib.
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Dasatinib.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Dasatinib.
HydromorphoneThe serum concentration of Hydromorphone can be increased when it is combined with Dasatinib.
Hydroxyprogesterone caproateThe serum concentration of Hydroxyprogesterone caproate can be increased when it is combined with Dasatinib.
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Dasatinib.
IbudilastDasatinib may increase the anticoagulant activities of Ibudilast.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Dasatinib.
IbutilideDasatinib may increase the QTc-prolonging activities of Ibutilide.
Icosapent ethylDasatinib may increase the anticoagulant activities of Icosapent ethyl.
IdelalisibThe serum concentration of Dasatinib can be increased when it is combined with Idelalisib.
IfenprodilDasatinib may increase the anticoagulant activities of Ifenprodil.
IfosfamideThe serum concentration of Ifosfamide can be increased when it is combined with Dasatinib.
IloperidoneThe serum concentration of Iloperidone can be increased when it is combined with Dasatinib.
IloprostDasatinib may increase the anticoagulant activities of Iloprost.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Dasatinib.
ImatinibThe metabolism of Dasatinib can be decreased when combined with Imatinib.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Dasatinib.
ImiquimodThe serum concentration of Imiquimod can be increased when it is combined with Dasatinib.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Dasatinib.
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Dasatinib.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Dasatinib.
IndinavirThe serum concentration of Dasatinib can be decreased when it is combined with Indinavir.
IndomethacinThe serum concentration of Dasatinib can be increased when it is combined with Indomethacin.
Ipratropium bromideThe serum concentration of Ipratropium bromide can be increased when it is combined with Dasatinib.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Dasatinib.
IsavuconazoniumThe serum concentration of Isavuconazonium can be increased when it is combined with Dasatinib.
IsavuconazoniumThe metabolism of Dasatinib can be decreased when combined with Isavuconazonium.
Isosorbide DinitrateThe serum concentration of Isosorbide Dinitrate can be increased when it is combined with Dasatinib.
Isosorbide MononitrateThe serum concentration of Isosorbide Mononitrate can be increased when it is combined with Dasatinib.
IsradipineThe serum concentration of Isradipine can be increased when it is combined with Dasatinib.
IsradipineThe metabolism of Dasatinib can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of Itraconazole can be increased when it is combined with Dasatinib.
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Dasatinib.
IvacaftorThe serum concentration of Ivacaftor can be increased when it is combined with Dasatinib.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Dasatinib.
IxabepiloneThe serum concentration of Ixabepilone can be increased when it is combined with Dasatinib.
IxazomibThe serum concentration of Ixazomib can be increased when it is combined with Dasatinib.
KetamineThe serum concentration of Ketamine can be increased when it is combined with Dasatinib.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Dasatinib.
KetobemidoneThe serum concentration of Ketobemidone can be increased when it is combined with Dasatinib.
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Dasatinib.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Dasatinib.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Dasatinib.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Dasatinib.
LansoprazoleThe serum concentration of Dasatinib can be decreased when it is combined with Lansoprazole.
LapatinibThe serum concentration of Lapatinib can be increased when it is combined with Dasatinib.
LaquinimodThe serum concentration of Laquinimod can be increased when it is combined with Dasatinib.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Dasatinib.
LeflunomideThe risk or severity of adverse effects can be increased when Dasatinib is combined with Leflunomide.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Dasatinib.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Dasatinib.
LepirudinDasatinib may increase the anticoagulant activities of Lepirudin.
LercanidipineThe serum concentration of Lercanidipine can be increased when it is combined with Dasatinib.
LetrozoleThe serum concentration of Letrozole can be increased when it is combined with Dasatinib.
LeuprolideDasatinib may increase the QTc-prolonging activities of Leuprolide.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Dasatinib.
LevobupivacaineThe serum concentration of Levobupivacaine can be increased when it is combined with Dasatinib.
LevocetirizineThe serum concentration of Levocetirizine can be increased when it is combined with Dasatinib.
LevofloxacinDasatinib may increase the QTc-prolonging activities of Levofloxacin.
LevofloxacinThe serum concentration of Dasatinib can be increased when it is combined with Levofloxacin.
Levomethadyl AcetateThe serum concentration of Levomethadyl Acetate can be increased when it is combined with Dasatinib.
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Dasatinib.
LevonorgestrelThe serum concentration of Levonorgestrel can be increased when it is combined with Dasatinib.
LevothyroxineThe serum concentration of Levothyroxine can be increased when it is combined with Dasatinib.
LevothyroxineThe serum concentration of Dasatinib can be decreased when it is combined with Levothyroxine.
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Dasatinib.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Dasatinib.
LiothyronineThe serum concentration of Dasatinib can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Dasatinib can be decreased when it is combined with Liotrix.
LisinoprilThe serum concentration of Dasatinib can be increased when it is combined with Lisinopril.
LisurideThe serum concentration of Lisuride can be increased when it is combined with Dasatinib.
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Dasatinib.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Dasatinib.
LopinavirThe serum concentration of Lopinavir can be increased when it is combined with Dasatinib.
LoratadineThe serum concentration of Loratadine can be increased when it is combined with Dasatinib.
LorcaserinThe serum concentration of Lorcaserin can be increased when it is combined with Dasatinib.
LosartanThe serum concentration of Losartan can be increased when it is combined with Dasatinib.
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Dasatinib.
LovastatinThe metabolism of Dasatinib can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Dasatinib can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Dasatinib can be decreased when it is combined with Lumacaftor.
LumefantrineThe serum concentration of Lumefantrine can be increased when it is combined with Dasatinib.
LurasidoneThe serum concentration of Lurasidone can be increased when it is combined with Dasatinib.
MacitentanThe serum concentration of Macitentan can be increased when it is combined with Dasatinib.
MagaldrateMagaldrate can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium carbonateMagnesium carbonate can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium hydroxideMagnesium hydroxide can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Dasatinib.
MaprotilineThe serum concentration of Dasatinib can be increased when it is combined with Maprotiline.
MaravirocThe serum concentration of Maraviroc can be increased when it is combined with Dasatinib.
MebendazoleThe serum concentration of Mebendazole can be increased when it is combined with Dasatinib.
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Dasatinib.
MefloquineThe serum concentration of Mefloquine can be increased when it is combined with Dasatinib.
Megestrol acetateThe serum concentration of Dasatinib can be increased when it is combined with Megestrol acetate.
MeloxicamThe serum concentration of Meloxicam can be increased when it is combined with Dasatinib.
MeprobamateThe serum concentration of Dasatinib can be increased when it is combined with Meprobamate.
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Dasatinib.
MethadoneThe serum concentration of Methadone can be increased when it is combined with Dasatinib.
MethanthelineMethantheline can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
MethaqualoneThe serum concentration of Methaqualone can be increased when it is combined with Dasatinib.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Dasatinib.
MethoxsalenThe serum concentration of Methoxsalen can be increased when it is combined with Dasatinib.
MethoxyfluraneThe serum concentration of Methoxyflurane can be increased when it is combined with Dasatinib.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Dasatinib.
MethyltestosteroneThe serum concentration of Methyltestosterone can be increased when it is combined with Dasatinib.
MetiamideMetiamide can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
MetoprololThe serum concentration of Dasatinib can be increased when it is combined with Metoprolol.
MetronidazoleThe serum concentration of Metronidazole can be increased when it is combined with Dasatinib.
MexiletineThe serum concentration of Mexiletine can be increased when it is combined with Dasatinib.
MexiletineThe metabolism of Dasatinib can be decreased when combined with Mexiletine.
MianserinThe serum concentration of Mianserin can be increased when it is combined with Dasatinib.
MibefradilThe serum concentration of Mibefradil can be increased when it is combined with Dasatinib.
MiconazoleThe serum concentration of Miconazole can be increased when it is combined with Dasatinib.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Dasatinib.
MidazolamThe serum concentration of Dasatinib can be decreased when it is combined with Midazolam.
MifepristoneThe serum concentration of Mifepristone can be increased when it is combined with Dasatinib.
MifepristoneThe metabolism of Dasatinib can be decreased when combined with Mifepristone.
MilrinoneDasatinib may increase the anticoagulant activities of Milrinone.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Dasatinib.
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Dasatinib.
MitomycinThe serum concentration of Dasatinib can be increased when it is combined with Mitomycin.
MitotaneThe serum concentration of Dasatinib can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Dasatinib can be decreased when it is combined with Mitoxantrone.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Dasatinib.
ModafinilThe serum concentration of Modafinil can be increased when it is combined with Dasatinib.
ModafinilThe serum concentration of Dasatinib can be decreased when it is combined with Modafinil.
MontelukastThe serum concentration of Montelukast can be increased when it is combined with Dasatinib.
MorphineThe serum concentration of Morphine can be increased when it is combined with Dasatinib.
MoxifloxacinDasatinib may increase the QTc-prolonging activities of Moxifloxacin.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Dasatinib.
NadololThe serum concentration of Nadolol can be increased when it is combined with Dasatinib.
NadroparinDasatinib may increase the anticoagulant activities of Nadroparin.
NafcillinThe serum concentration of Dasatinib can be decreased when it is combined with Nafcillin.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Dasatinib.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Dasatinib.
NaltrexoneThe serum concentration of Dasatinib can be increased when it is combined with Naltrexone.
NaringeninThe serum concentration of Dasatinib can be increased when it is combined with Naringenin.
NatalizumabThe risk or severity of adverse effects can be increased when Dasatinib is combined with Natalizumab.
NateglinideThe serum concentration of Nateglinide can be increased when it is combined with Dasatinib.
NCX 4016Dasatinib may increase the anticoagulant activities of NCX 4016.
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Dasatinib.
NefazodoneThe serum concentration of Dasatinib can be decreased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Dasatinib.
NelfinavirThe serum concentration of Dasatinib can be decreased when it is combined with Nelfinavir.
NeostigmineThe serum concentration of Dasatinib can be increased when it is combined with Neostigmine.
NetupitantThe serum concentration of Dasatinib can be increased when it is combined with Netupitant.
NevirapineThe serum concentration of Nevirapine can be increased when it is combined with Dasatinib.
NevirapineThe metabolism of Dasatinib can be decreased when combined with Nevirapine.
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Dasatinib.
NicotineThe serum concentration of Nicotine can be increased when it is combined with Dasatinib.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Dasatinib.
NifedipineThe serum concentration of Dasatinib can be decreased when it is combined with Nifedipine.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Dasatinib.
NilotinibThe metabolism of Dasatinib can be decreased when combined with Nilotinib.
NilvadipineThe serum concentration of Nilvadipine can be increased when it is combined with Dasatinib.
NimesulideDasatinib may increase the anticoagulant activities of Nimesulide.
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Dasatinib.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Dasatinib.
NisoldipineThe serum concentration of Nisoldipine can be increased when it is combined with Dasatinib.
NitrazepamThe serum concentration of Nitrazepam can be increased when it is combined with Dasatinib.
NitrendipineThe serum concentration of Nitrendipine can be increased when it is combined with Dasatinib.
NizatidineNizatidine can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Dasatinib.
NorethisteroneThe serum concentration of Norethisterone can be increased when it is combined with Dasatinib.
NorethisteroneThe serum concentration of Dasatinib can be decreased when it is combined with Norethisterone.
NorgestrelThe serum concentration of Norgestrel can be increased when it is combined with Dasatinib.
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Dasatinib.
OfloxacinDasatinib may increase the QTc-prolonging activities of Ofloxacin.
OlanzapineOlanzapine can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Dasatinib.
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Dasatinib.
OlaparibThe metabolism of Dasatinib can be decreased when combined with Olaparib.
OlopatadineThe serum concentration of Olopatadine can be increased when it is combined with Dasatinib.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Dasatinib.
OmeprazoleThe serum concentration of Omeprazole can be increased when it is combined with Dasatinib.
OmeprazoleThe serum concentration of Dasatinib can be decreased when it is combined with Omeprazole.
OndansetronThe serum concentration of Ondansetron can be increased when it is combined with Dasatinib.
OrphenadrineThe serum concentration of Orphenadrine can be increased when it is combined with Dasatinib.
OsimertinibThe serum concentration of Dasatinib can be increased when it is combined with Osimertinib.
OspemifeneThe serum concentration of Ospemifene can be increased when it is combined with Dasatinib.
OtamixabanDasatinib may increase the anticoagulant activities of Otamixaban.
OuabainOuabain may decrease the cardiotoxic activities of Dasatinib.
OxazepamThe serum concentration of Oxazepam can be increased when it is combined with Dasatinib.
OxybutyninThe serum concentration of Oxybutynin can be increased when it is combined with Dasatinib.
OxycodoneThe serum concentration of Oxycodone can be increased when it is combined with Dasatinib.
OxymorphoneThe serum concentration of Oxymorphone can be increased when it is combined with Dasatinib.
P-NitrophenolThe serum concentration of Dasatinib can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Dasatinib.
PalbociclibThe serum concentration of Palbociclib can be increased when it is combined with Dasatinib.
PaliperidoneDasatinib may increase the QTc-prolonging activities of Paliperidone.
Palmitic AcidThe serum concentration of Dasatinib can be increased when it is combined with Palmitic Acid.
PalonosetronThe serum concentration of Palonosetron can be increased when it is combined with Dasatinib.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Dasatinib.
PantoprazoleThe serum concentration of Pantoprazole can be increased when it is combined with Dasatinib.
PantoprazoleThe serum concentration of Dasatinib can be decreased when it is combined with Pantoprazole.
ParamethadioneThe serum concentration of Paramethadione can be increased when it is combined with Dasatinib.
ParamethasoneThe serum concentration of Paramethasone can be increased when it is combined with Dasatinib.
ParecoxibThe serum concentration of Parecoxib can be increased when it is combined with Dasatinib.
ParicalcitolThe serum concentration of Paricalcitol can be increased when it is combined with Dasatinib.
ParitaprevirThe serum concentration of Paritaprevir can be increased when it is combined with Dasatinib.
ParoxetineThe serum concentration of Dasatinib can be increased when it is combined with Paroxetine.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Dasatinib.
Peginterferon alfa-2bThe serum concentration of Dasatinib can be increased when it is combined with Peginterferon alfa-2b.
PentamidineThe serum concentration of Pentamidine can be increased when it is combined with Dasatinib.
PentobarbitalThe serum concentration of Dasatinib can be decreased when it is combined with Pentobarbital.
Pentosan PolysulfateDasatinib may increase the anticoagulant activities of Pentosan Polysulfate.
PentoxifyllineDasatinib may increase the anticoagulant activities of Pentoxifylline.
PerampanelThe serum concentration of Perampanel can be increased when it is combined with Dasatinib.
PerflutrenDasatinib may increase the QTc-prolonging activities of Perflutren.
PergolideThe serum concentration of Pergolide can be increased when it is combined with Dasatinib.
PerhexilineThe serum concentration of Perhexiline can be increased when it is combined with Dasatinib.
PerindoprilThe serum concentration of Dasatinib can be increased when it is combined with Perindopril.
PermethrinThe serum concentration of Permethrin can be increased when it is combined with Dasatinib.
PerphenazineThe serum concentration of Perphenazine can be increased when it is combined with Dasatinib.
PethidineThe serum concentration of Pethidine can be increased when it is combined with Dasatinib.
PhenacetinThe serum concentration of Phenacetin can be increased when it is combined with Dasatinib.
PhenindioneDasatinib may increase the anticoagulant activities of Phenindione.
PhenobarbitalThe serum concentration of Dasatinib can be decreased when it is combined with Phenobarbital.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Dasatinib.
PhenoxybenzamineThe serum concentration of Phenoxybenzamine can be increased when it is combined with Dasatinib.
PhenprocoumonDasatinib may increase the anticoagulant activities of Phenprocoumon.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Dasatinib.
PhenytoinThe serum concentration of Dasatinib can be decreased when it is combined with Phenytoin.
PilocarpineThe serum concentration of Pilocarpine can be increased when it is combined with Dasatinib.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Dasatinib.
PimecrolimusThe serum concentration of Pimecrolimus can be increased when it is combined with Dasatinib.
PimozideThe serum concentration of Pimozide can be increased when it is combined with Dasatinib.
PinacidilThe serum concentration of Pinacidil can be increased when it is combined with Dasatinib.
PioglitazoneThe serum concentration of Pioglitazone can be increased when it is combined with Dasatinib.
PipotiazineThe serum concentration of Pipotiazine can be increased when it is combined with Dasatinib.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Dasatinib.
Platelet Activating FactorThe serum concentration of Dasatinib can be decreased when it is combined with Platelet Activating Factor.
PodofiloxThe serum concentration of Podofilox can be increased when it is combined with Dasatinib.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Dasatinib.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Dasatinib.
PosaconazoleThe serum concentration of Posaconazole can be increased when it is combined with Dasatinib.
PrasugrelDasatinib may increase the anticoagulant activities of Prasugrel.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Dasatinib.
PrazepamThe serum concentration of Prazepam can be increased when it is combined with Dasatinib.
PraziquantelThe serum concentration of Praziquantel can be increased when it is combined with Dasatinib.
PrazosinThe serum concentration of Dasatinib can be increased when it is combined with Prazosin.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Dasatinib.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Dasatinib.
PrimaquineThe serum concentration of Primaquine can be increased when it is combined with Dasatinib.
PrimidoneThe serum concentration of Dasatinib can be decreased when it is combined with Primidone.
ProbenecidThe serum concentration of Dasatinib can be increased when it is combined with Probenecid.
ProcainamideDasatinib may increase the QTc-prolonging activities of Procainamide.
ProchlorperazineThe serum concentration of Prochlorperazine can be increased when it is combined with Dasatinib.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Dasatinib.
ProgesteroneThe serum concentration of Dasatinib can be decreased when it is combined with Progesterone.
ProguanilThe serum concentration of Proguanil can be increased when it is combined with Dasatinib.
PromazineThe serum concentration of Promazine can be increased when it is combined with Dasatinib.
PromethazineThe serum concentration of Dasatinib can be increased when it is combined with Promethazine.
PropacetamolDasatinib may increase the hepatotoxic activities of Propacetamol.
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Dasatinib.
PropofolThe serum concentration of Propofol can be increased when it is combined with Dasatinib.
PropranololThe serum concentration of Propranolol can be increased when it is combined with Dasatinib.
Protein CDasatinib may increase the anticoagulant activities of Protein C.
ProtocatechualdehydeDasatinib may increase the anticoagulant activities of Protocatechualdehyde.
ProtriptylineThe serum concentration of Dasatinib can be increased when it is combined with Protriptyline.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Dasatinib.
PyrazinamideThe serum concentration of Pyrazinamide can be increased when it is combined with Dasatinib.
QuazepamThe serum concentration of Quazepam can be increased when it is combined with Dasatinib.
QuercetinThe serum concentration of Dasatinib can be increased when it is combined with Quercetin.
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Dasatinib.
QuinacrineThe serum concentration of Quinacrine can be increased when it is combined with Dasatinib.
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Dasatinib.
QuinineThe serum concentration of Quinine can be increased when it is combined with Dasatinib.
RabeprazoleThe serum concentration of Rabeprazole can be increased when it is combined with Dasatinib.
RabeprazoleThe serum concentration of Dasatinib can be decreased when it is combined with Rabeprazole.
Rabies vaccineThe risk or severity of adverse effects can be increased when Dasatinib is combined with Rabies vaccine.
RaloxifeneThe serum concentration of Raloxifene can be increased when it is combined with Dasatinib.
RamelteonThe serum concentration of Ramelteon can be increased when it is combined with Dasatinib.
RanitidineRanitidine can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Dasatinib.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Dasatinib.
ReboxetineThe serum concentration of Reboxetine can be increased when it is combined with Dasatinib.
RegorafenibThe serum concentration of Regorafenib can be increased when it is combined with Dasatinib.
RepaglinideThe serum concentration of Repaglinide can be increased when it is combined with Dasatinib.
ReserpineThe serum concentration of Dasatinib can be decreased when it is combined with Reserpine.
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Dasatinib.
ResveratrolDasatinib may increase the anticoagulant activities of Resveratrol.
RetapamulinThe serum concentration of Retapamulin can be increased when it is combined with Dasatinib.
ReviparinDasatinib may increase the anticoagulant activities of Reviparin.
RidogrelDasatinib may increase the anticoagulant activities of Ridogrel.
RifabutinThe serum concentration of Rifabutin can be increased when it is combined with Dasatinib.
RifabutinThe serum concentration of Dasatinib can be decreased when it is combined with Rifabutin.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Dasatinib.
RifampicinThe serum concentration of Dasatinib can be decreased when it is combined with Rifampicin.
RifapentineThe serum concentration of Dasatinib can be decreased when it is combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Dasatinib.
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Dasatinib.
RimonabantThe serum concentration of Rimonabant can be increased when it is combined with Dasatinib.
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Dasatinib.
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Dasatinib.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Dasatinib.
RitonavirThe serum concentration of Dasatinib can be decreased when it is combined with Ritonavir.
RivaroxabanDasatinib may increase the anticoagulant activities of Rivaroxaban.
RofecoxibThe serum concentration of Rofecoxib can be increased when it is combined with Dasatinib.
RoflumilastRoflumilast may increase the immunosuppressive activities of Dasatinib.
RolapitantThe serum concentration of Rolapitant can be increased when it is combined with Dasatinib.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Dasatinib.
RopiniroleThe serum concentration of Ropinirole can be increased when it is combined with Dasatinib.
RopiniroleThe metabolism of Dasatinib can be decreased when combined with Ropinirole.
RopivacaineThe serum concentration of Ropivacaine can be increased when it is combined with Dasatinib.
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Dasatinib.
RotigotineThe serum concentration of Rotigotine can be increased when it is combined with Dasatinib.
Roxatidine acetateRoxatidine acetate can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
RoxithromycinThe serum concentration of Roxithromycin can be increased when it is combined with Dasatinib.
RuxolitinibThe serum concentration of Ruxolitinib can be increased when it is combined with Dasatinib.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Dasatinib.
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Dasatinib.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Dasatinib.
SaquinavirThe serum concentration of Dasatinib can be decreased when it is combined with Saquinavir.
SaxagliptinThe serum concentration of Saxagliptin can be increased when it is combined with Dasatinib.
SCH-530348Dasatinib may increase the anticoagulant activities of SCH-530348.
ScopolamineThe serum concentration of Dasatinib can be increased when it is combined with Scopolamine.
SelegilineThe serum concentration of Selegiline can be increased when it is combined with Dasatinib.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Dasatinib.
SeratrodastThe serum concentration of Seratrodast can be increased when it is combined with Dasatinib.
SertindoleThe serum concentration of Sertindole can be increased when it is combined with Dasatinib.
SertralineThe serum concentration of Sertraline can be increased when it is combined with Dasatinib.
SevofluraneDasatinib may increase the anticoagulant activities of Sevoflurane.
SibutramineThe serum concentration of Sibutramine can be increased when it is combined with Dasatinib.
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Dasatinib.
SildenafilThe metabolism of Dasatinib can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Dasatinib.
SiltuximabThe serum concentration of Dasatinib can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Dasatinib.
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Dasatinib.
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Dasatinib.
SirolimusThe serum concentration of Sirolimus can be increased when it is combined with Dasatinib.
SirolimusThe serum concentration of Dasatinib can be decreased when it is combined with Sirolimus.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Dasatinib.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Dasatinib.
SolifenacinThe serum concentration of Solifenacin can be increased when it is combined with Dasatinib.
SonidegibThe serum concentration of Sonidegib can be increased when it is combined with Dasatinib.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Dasatinib.
SotalolDasatinib may increase the QTc-prolonging activities of Sotalol.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Dasatinib.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Dasatinib.
SpiramycinThe serum concentration of Spiramycin can be increased when it is combined with Dasatinib.
SpironolactoneThe serum concentration of Dasatinib can be increased when it is combined with Spironolactone.
SRT501Dasatinib may increase the anticoagulant activities of SRT501.
St. John's WortThe serum concentration of Dasatinib can be decreased when it is combined with St. John's Wort.
StaurosporineThe serum concentration of Dasatinib can be increased when it is combined with Staurosporine.
StiripentolThe serum concentration of Dasatinib can be increased when it is combined with Stiripentol.
StreptozocinThe serum concentration of Dasatinib can be decreased when it is combined with Streptozocin.
SufentanilThe serum concentration of Sufentanil can be increased when it is combined with Dasatinib.
SulfadiazineThe serum concentration of Sulfadiazine can be increased when it is combined with Dasatinib.
SulfamethoxazoleThe serum concentration of Sulfamethoxazole can be increased when it is combined with Dasatinib.
SulfinpyrazoneThe serum concentration of Sulfinpyrazone can be increased when it is combined with Dasatinib.
SulfisoxazoleDasatinib may increase the QTc-prolonging activities of Sulfisoxazole.
SulfisoxazoleThe metabolism of Dasatinib can be decreased when combined with Sulfisoxazole.
SulodexideDasatinib may increase the anticoagulant activities of Sulodexide.
SumatriptanThe serum concentration of Dasatinib can be increased when it is combined with Sumatriptan.
SunitinibThe serum concentration of Sunitinib can be increased when it is combined with Dasatinib.
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be increased when it is combined with Dasatinib.
Synthetic Conjugated Estrogens, BThe serum concentration of Synthetic Conjugated Estrogens, B can be increased when it is combined with Dasatinib.
TacrineThe serum concentration of Dasatinib can be increased when it is combined with Tacrine.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Dasatinib.
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Dasatinib.
TadalafilThe serum concentration of Tadalafil can be increased when it is combined with Dasatinib.
TAK-390MRThe serum concentration of Dasatinib can be decreased when it is combined with TAK-390MR.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Dasatinib.
TamoxifenThe serum concentration of Dasatinib can be decreased when it is combined with Tamoxifen.
TamsulosinThe serum concentration of Tamsulosin can be increased when it is combined with Dasatinib.
TasosartanThe serum concentration of Tasosartan can be increased when it is combined with Dasatinib.
Taurochenodeoxycholic acidThe serum concentration of Taurochenodeoxycholic acid can be increased when it is combined with Dasatinib.
Taurocholic AcidThe serum concentration of Dasatinib can be increased when it is combined with Taurocholic Acid.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Dasatinib.
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Dasatinib.
TelavancinDasatinib may increase the QTc-prolonging activities of Telavancin.
TelithromycinThe serum concentration of Telithromycin can be increased when it is combined with Dasatinib.
TelmisartanThe serum concentration of Dasatinib can be increased when it is combined with Telmisartan.
TemazepamThe serum concentration of Temazepam can be increased when it is combined with Dasatinib.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Dasatinib.
TeniposideThe serum concentration of Teniposide can be increased when it is combined with Dasatinib.
TenofovirThe metabolism of Dasatinib can be decreased when combined with Tenofovir.
TerazosinThe serum concentration of Dasatinib can be increased when it is combined with Terazosin.
TerbinafineThe serum concentration of Terbinafine can be increased when it is combined with Dasatinib.
TerfenadineThe serum concentration of Terfenadine can be increased when it is combined with Dasatinib.
TeriflunomideThe serum concentration of Dasatinib can be decreased when it is combined with Teriflunomide.
TesmilifeneDasatinib may increase the anticoagulant activities of Tesmilifene.
TesmilifeneThe serum concentration of Dasatinib can be decreased when it is combined with Tesmilifene.
TestosteroneThe serum concentration of Testosterone can be increased when it is combined with Dasatinib.
TetrabenazineDasatinib may increase the QTc-prolonging activities of Tetrabenazine.
TetracyclineThe serum concentration of Tetracycline can be increased when it is combined with Dasatinib.
TheophyllineThe serum concentration of Theophylline can be increased when it is combined with Dasatinib.
TheophyllineThe metabolism of Dasatinib can be decreased when combined with Theophylline.
ThioridazineDasatinib may increase the QTc-prolonging activities of Thioridazine.
ThiotepaThe serum concentration of Thiotepa can be increased when it is combined with Dasatinib.
TiagabineThe serum concentration of Tiagabine can be increased when it is combined with Dasatinib.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Dasatinib.
TiclopidineDasatinib may increase the anticoagulant activities of Ticlopidine.
TiclopidineThe metabolism of Dasatinib can be decreased when combined with Ticlopidine.
TimololThe serum concentration of Timolol can be increased when it is combined with Dasatinib.
TinidazoleThe serum concentration of Tinidazole can be increased when it is combined with Dasatinib.
TiotropiumThe serum concentration of Tiotropium can be increased when it is combined with Dasatinib.
TipranavirThe serum concentration of Tipranavir can be increased when it is combined with Dasatinib.
TirofibanDasatinib may increase the anticoagulant activities of Tirofiban.
TocilizumabThe serum concentration of Dasatinib can be decreased when it is combined with Tocilizumab.
TofacitinibDasatinib may increase the immunosuppressive activities of Tofacitinib.
TolterodineThe serum concentration of Tolterodine can be increased when it is combined with Dasatinib.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Dasatinib.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Dasatinib.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Dasatinib.
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Dasatinib.
TramadolThe serum concentration of Tramadol can be increased when it is combined with Dasatinib.
TranilastDasatinib may increase the anticoagulant activities of Tranilast.
TrapidilDasatinib may increase the anticoagulant activities of Trapidil.
TrastuzumabTrastuzumab may increase the neutropenic activities of Dasatinib.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Dasatinib.
TrazodoneThe serum concentration of Trazodone can be increased when it is combined with Dasatinib.
TrazodoneThe serum concentration of Dasatinib can be decreased when it is combined with Trazodone.
TretinoinThe serum concentration of Tretinoin can be increased when it is combined with Dasatinib.
TriamcinoloneThe serum concentration of Triamcinolone can be increased when it is combined with Dasatinib.
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Dasatinib.
TrifluoperazineThe serum concentration of Dasatinib can be increased when it is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Dasatinib can be increased when it is combined with Triflupromazine.
TriflusalDasatinib may increase the anticoagulant activities of Triflusal.
TrimethadioneThe serum concentration of Trimethadione can be increased when it is combined with Dasatinib.
TrimethoprimThe serum concentration of Trimethoprim can be increased when it is combined with Dasatinib.
TrimethoprimThe serum concentration of Dasatinib can be decreased when it is combined with Trimethoprim.
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Dasatinib.
TroglitazoneThe serum concentration of Troglitazone can be increased when it is combined with Dasatinib.
TroleandomycinThe serum concentration of Troleandomycin can be increased when it is combined with Dasatinib.
UdenafilThe serum concentration of Udenafil can be increased when it is combined with Dasatinib.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Dasatinib.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Dasatinib.
ValdecoxibThe serum concentration of Valdecoxib can be increased when it is combined with Dasatinib.
VandetanibThe serum concentration of Vandetanib can be increased when it is combined with Dasatinib.
VanoxerineThe serum concentration of Vanoxerine can be increased when it is combined with Dasatinib.
VardenafilThe serum concentration of Vardenafil can be increased when it is combined with Dasatinib.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Dasatinib.
VemurafenibThe serum concentration of Vemurafenib can be increased when it is combined with Dasatinib.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Dasatinib.
VenlafaxineThe metabolism of Dasatinib can be decreased when combined with Venlafaxine.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Dasatinib.
VerapamilThe metabolism of Dasatinib can be decreased when combined with Verapamil.
VicrivirocThe serum concentration of Vicriviroc can be increased when it is combined with Dasatinib.
VilanterolThe serum concentration of Vilanterol can be increased when it is combined with Dasatinib.
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Dasatinib.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Dasatinib.
VinblastineThe serum concentration of Dasatinib can be decreased when it is combined with Vinblastine.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Dasatinib.
VincristineThe serum concentration of Dasatinib can be decreased when it is combined with Vincristine.
VindesineThe serum concentration of Vindesine can be increased when it is combined with Dasatinib.
VinorelbineThe serum concentration of Vinorelbine can be increased when it is combined with Dasatinib.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Dasatinib.
VorapaxarDasatinib may increase the anticoagulant activities of Vorapaxar.
VoriconazoleThe serum concentration of Voriconazole can be increased when it is combined with Dasatinib.
VortioxetineThe serum concentration of Vortioxetine can be increased when it is combined with Dasatinib.
WarfarinDasatinib may increase the anticoagulant activities of Warfarin.
XimelagatranDasatinib may increase the anticoagulant activities of Ximelagatran.
YohimbineThe serum concentration of Yohimbine can be increased when it is combined with Dasatinib.
ZafirlukastThe serum concentration of Zafirlukast can be increased when it is combined with Dasatinib.
ZalcitabineThe serum concentration of Zalcitabine can be increased when it is combined with Dasatinib.
ZaleplonThe serum concentration of Zaleplon can be increased when it is combined with Dasatinib.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Dasatinib.
ZileutonThe serum concentration of Zileuton can be increased when it is combined with Dasatinib.
ZimelidineThe serum concentration of Dasatinib can be increased when it is combined with Zimelidine.
ZiprasidoneThe serum concentration of Ziprasidone can be increased when it is combined with Dasatinib.
ZiprasidoneThe metabolism of Dasatinib can be decreased when combined with Ziprasidone.
ZolpidemThe serum concentration of Zolpidem can be increased when it is combined with Dasatinib.
ZomepiracThe serum concentration of Zomepirac can be increased when it is combined with Dasatinib.
ZonisamideThe serum concentration of Zonisamide can be increased when it is combined with Dasatinib.
ZopicloneThe serum concentration of Zopiclone can be increased when it is combined with Dasatinib.
ZuclopenthixolDasatinib may increase the QTc-prolonging activities of Zuclopenthixol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
multitarget
General Function:
Syntaxin binding
Specific Function:
Non-receptor tyrosine-protein kinase that plays a role in many key processes linked to cell growth and survival such as cytoskeleton remodeling in response to extracellular stimuli, cell motility and adhesion, receptor endocytosis, autophagy, DNA damage response and apoptosis. Coordinates actin remodeling through tyrosine phosphorylation of proteins controlling cytoskeleton dynamics like WASF3 ...
Gene Name:
ABL1
Uniprot ID:
P00519
Molecular Weight:
122871.435 Da
References
  1. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  2. Piccaluga PP, Paolini S, Martinelli G: Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Cancer. 2007 Sep 15;110(6):1178-86. [PubMed:17701954 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
multitarget
General Function:
Sh3/sh2 adaptor activity
Specific Function:
Non-receptor protein tyrosine kinase which is activated following engagement of many different classes of cellular receptors including immune response receptors, integrins and other adhesion receptors, receptor protein tyrosine kinases, G protein-coupled receptors as well as cytokine receptors. Participates in signaling pathways that control a diverse spectrum of biological activities including...
Gene Name:
SRC
Uniprot ID:
P12931
Molecular Weight:
59834.295 Da
References
  1. Kamath AV, Wang J, Lee FY, Marathe PH: Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. Cancer Chemother Pharmacol. 2008 Mar;61(3):365-76. Epub 2007 Apr 11. [PubMed:17429625 ]
  2. Serrels A, Macpherson IR, Evans TR, Lee FY, Clark EA, Sansom OJ, Ashton GH, Frame MC, Brunton VG: Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib. Mol Cancer Ther. 2006 Dec;5(12):3014-22. Epub 2006 Dec 5. [PubMed:17148760 ]
  3. Quintas-Cardama A, Kantarjian H, Cortes J: Targeting ABL and SRC kinases in chronic myeloid leukemia: experience with dasatinib. Future Oncol. 2006 Dec;2(6):655-65. [PubMed:17155893 ]
  4. Schittenhelm MM, Shiraga S, Schroeder A, Corbin AS, Griffith D, Lee FY, Bokemeyer C, Deininger MW, Druker BJ, Heinrich MC: Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res. 2006 Jan 1;66(1):473-81. [PubMed:16397263 ]
  5. Nam S, Kim D, Cheng JQ, Zhang S, Lee JH, Buettner R, Mirosevich J, Lee FY, Jove R: Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res. 2005 Oct 15;65(20):9185-9. [PubMed:16230377 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Transmembrane receptor protein tyrosine kinase activity
Specific Function:
Receptor tyrosine kinase which binds promiscuously membrane-bound ephrin-A family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Activated by the lig...
Gene Name:
EPHA2
Uniprot ID:
P29317
Molecular Weight:
108265.585 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Lindauer M, Hochhaus A: Dasatinib. Recent Results Cancer Res. 2010;184:83-102. doi: 10.1007/978-3-642-01222-8_7. [PubMed:20072833 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
multitarget
General Function:
Sh2 domain binding
Specific Function:
Non-receptor tyrosine-protein kinase that plays an essential role in the selection and maturation of developing T-cells in the thymus and in the function of mature T-cells. Plays a key role in T-cell antigen receptor (TCR)-linked signal transduction pathways. Constitutively associated with the cytoplasmic portions of the CD4 and CD8 surface receptors. Association of the TCR with a peptide antig...
Gene Name:
LCK
Uniprot ID:
P06239
Molecular Weight:
58000.15 Da
References
  1. Das J, Chen P, Norris D, Padmanabha R, Lin J, Moquin RV, Shen Z, Cook LS, Doweyko AM, Pitt S, Pang S, Shen DR, Fang Q, de Fex HF, McIntyre KW, Shuster DJ, Gillooly KM, Behnia K, Schieven GL, Wityak J, Barrish JC: 2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor. J Med Chem. 2006 Nov 16;49(23):6819-32. [PubMed:17154512 ]
  2. Lindauer M, Hochhaus A: Dasatinib. Recent Results Cancer Res. 2010;184:83-102. doi: 10.1007/978-3-642-01222-8_7. [PubMed:20072833 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Receptor binding
Specific Function:
Non-receptor protein tyrosine kinase that is involved in the regulation of cell growth and survival, apoptosis, cell-cell adhesion, cytoskeleton remodeling, and differentiation. Stimulation by receptor tyrosine kinases (RTKs) including EGRF, PDGFR, CSF1R and FGFR leads to recruitment of YES1 to the phosphorylated receptor, and activation and phosphorylation of downstream substrates. Upon EGFR a...
Gene Name:
YES1
Uniprot ID:
P07947
Molecular Weight:
60800.78 Da
References
  1. Trevino JG, Summy JM, Lesslie DP, Parikh NU, Hong DS, Lee FY, Donato NJ, Abbruzzese JL, Baker CH, Gallick GE: Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. Am J Pathol. 2006 Mar;168(3):962-72. [PubMed:16507911 ]
  2. Margutti S, Laufer SA: Are MAP kinases drug targets? Yes, but difficult ones. ChemMedChem. 2007 Aug;2(8):1116-40. [PubMed:17541990 ]
  3. Lindauer M, Hochhaus A: Dasatinib. Recent Results Cancer Res. 2010;184:83-102. doi: 10.1007/978-3-642-01222-8_7. [PubMed:20072833 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Transmembrane receptor protein tyrosine kinase activity
Specific Function:
Tyrosine-protein kinase that acts as cell-surface receptor for the cytokine KITLG/SCF and plays an essential role in the regulation of cell survival and proliferation, hematopoiesis, stem cell maintenance, gametogenesis, mast cell development, migration and function, and in melanogenesis. In response to KITLG/SCF binding, KIT can activate several signaling pathways. Phosphorylates PIK3R1, PLCG1...
Gene Name:
KIT
Uniprot ID:
P10721
Molecular Weight:
109863.655 Da
References
  1. Schittenhelm MM, Shiraga S, Schroeder A, Corbin AS, Griffith D, Lee FY, Bokemeyer C, Deininger MW, Druker BJ, Heinrich MC: Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res. 2006 Jan 1;66(1):473-81. [PubMed:16397263 ]
  2. Shah NP, Lee FY, Luo R, Jiang Y, Donker M, Akin C: Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood. 2006 Jul 1;108(1):286-91. Epub 2006 Jan 24. [PubMed:16434489 ]
  3. Dizdar O, Dede DS, Bulut N, Altundag K: Dasatinib may also inhibit c-Kit in triple negative breast cancer cell lines. Breast Cancer Res Treat. 2008 Jan;107(2):303. Epub 2007 Mar 10. [PubMed:17351742 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Vascular endothelial growth factor binding
Specific Function:
Tyrosine-protein kinase that acts as cell-surface receptor for homodimeric PDGFB and PDGFD and for heterodimers formed by PDGFA and PDGFB, and plays an essential role in the regulation of embryonic development, cell proliferation, survival, differentiation, chemotaxis and migration. Plays an essential role in blood vessel development by promoting proliferation, migration and recruitment of peri...
Gene Name:
PDGFRB
Uniprot ID:
P09619
Molecular Weight:
123966.895 Da
References
  1. Zhang Z, Meier KE: New assignments for multitasking signal transduction inhibitors. Mol Pharmacol. 2006 May;69(5):1510-2. Epub 2006 Feb 23. [PubMed:16497876 ]
  2. Chen Z, Lee FY, Bhalla KN, Wu J: Potent inhibition of platelet-derived growth factor-induced responses in vascular smooth muscle cells by BMS-354825 (dasatinib). Mol Pharmacol. 2006 May;69(5):1527-33. Epub 2006 Jan 25. [PubMed:16436588 ]
  3. Lindauer M, Hochhaus A: Dasatinib. Recent Results Cancer Res. 2010;184:83-102. doi: 10.1007/978-3-642-01222-8_7. [PubMed:20072833 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Transcription factor activity, sequence-specific dna binding
Specific Function:
Carries out a dual function: signal transduction and activation of transcription. Mediates cellular responses to the cytokine KITLG/SCF and other growth factors. Binds to the GAS element and activates PRL-induced transcription.
Gene Name:
STAT5B
Uniprot ID:
P51692
Molecular Weight:
89865.35 Da
References
  1. Fiskus W, Pranpat M, Balasis M, Bali P, Estrella V, Kumaraswamy S, Rao R, Rocha K, Herger B, Lee F, Richon V, Bhalla K: Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells. Clin Cancer Res. 2006 Oct 1;12(19):5869-78. [PubMed:17020995 ]
  2. Nam S, Williams A, Vultur A, List A, Bhalla K, Smith D, Lee FY, Jove R: Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells. Mol Cancer Ther. 2007 Apr;6(4):1400-5. [PubMed:17431118 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
multitarget
General Function:
Receptor binding
Specific Function:
Non-receptor tyrosine-protein kinase that plays an ABL1-overlapping role in key processes linked to cell growth and survival such as cytoskeleton remodeling in response to extracellular stimuli, cell motility and adhesion and receptor endocytosis. Coordinates actin remodeling through tyrosine phosphorylation of proteins controlling cytoskeleton dynamics like MYH10 (involved in movement); CTTN (...
Gene Name:
ABL2
Uniprot ID:
P42684
Molecular Weight:
128341.935 Da
References
  1. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  2. Lindauer M, Hochhaus A: Dasatinib. Recent Results Cancer Res. 2010;184:83-102. doi: 10.1007/978-3-642-01222-8_7. [PubMed:20072833 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
multitarget
General Function:
Protein tyrosine kinase activity
Specific Function:
Non-receptor tyrosine-protein kinase that plays a role in many biological processes including regulation of cell growth and survival, cell adhesion, integrin-mediated signaling, cytoskeletal remodeling, cell motility, immune response and axon guidance. Inactive FYN is phosphorylated on its C-terminal tail within the catalytic domain. Following activation by PKA, the protein subsequently associa...
Gene Name:
FYN
Uniprot ID:
P06241
Molecular Weight:
60761.49 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Lindauer M, Hochhaus A: Dasatinib. Recent Results Cancer Res. 2010;184:83-102. doi: 10.1007/978-3-642-01222-8_7. [PubMed:20072833 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. van Erp NP, Gelderblom H, Guchelaar HJ: Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706. doi: 10.1016/j.ctrv.2009.08.004. Epub 2009 Sep 5. [PubMed:19733976 ]
  2. Wang L, Christopher LJ, Cui D, Li W, Iyer R, Humphreys WG, Zhang D: Identification of the human enzymes involved in the oxidative metabolism of dasatinib: an effective approach for determining metabolite formation kinetics. Drug Metab Dispos. 2008 Sep;36(9):1828-39. doi: 10.1124/dmd.107.020255. Epub 2008 Jun 12. [PubMed:18556438 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. van Erp NP, Gelderblom H, Guchelaar HJ: Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706. doi: 10.1016/j.ctrv.2009.08.004. Epub 2009 Sep 5. [PubMed:19733976 ]
  2. Wang L, Christopher LJ, Cui D, Li W, Iyer R, Humphreys WG, Zhang D: Identification of the human enzymes involved in the oxidative metabolism of dasatinib: an effective approach for determining metabolite formation kinetics. Drug Metab Dispos. 2008 Sep;36(9):1828-39. doi: 10.1124/dmd.107.020255. Epub 2008 Jun 12. [PubMed:18556438 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. van Erp NP, Gelderblom H, Guchelaar HJ: Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706. doi: 10.1016/j.ctrv.2009.08.004. Epub 2009 Sep 5. [PubMed:19733976 ]
  2. Wang L, Christopher LJ, Cui D, Li W, Iyer R, Humphreys WG, Zhang D: Identification of the human enzymes involved in the oxidative metabolism of dasatinib: an effective approach for determining metabolite formation kinetics. Drug Metab Dispos. 2008 Sep;36(9):1828-39. doi: 10.1124/dmd.107.020255. Epub 2008 Jun 12. [PubMed:18556438 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, retinoid and xenobiotics. Preferentially oxidizes 17beta-estradiol to the carcinogenic 4-hydroxy derivative, and a variety of procarcinogenic compou...
Gene Name:
CYP1B1
Uniprot ID:
Q16678
Molecular Weight:
60845.33 Da
References
  1. van Erp NP, Gelderblom H, Guchelaar HJ: Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706. doi: 10.1016/j.ctrv.2009.08.004. Epub 2009 Sep 5. [PubMed:19733976 ]
  2. Wang L, Christopher LJ, Cui D, Li W, Iyer R, Humphreys WG, Zhang D: Identification of the human enzymes involved in the oxidative metabolism of dasatinib: an effective approach for determining metabolite formation kinetics. Drug Metab Dispos. 2008 Sep;36(9):1828-39. doi: 10.1124/dmd.107.020255. Epub 2008 Jun 12. [PubMed:18556438 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. van Erp NP, Gelderblom H, Guchelaar HJ: Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706. doi: 10.1016/j.ctrv.2009.08.004. Epub 2009 Sep 5. [PubMed:19733976 ]
  2. Wang L, Christopher LJ, Cui D, Li W, Iyer R, Humphreys WG, Zhang D: Identification of the human enzymes involved in the oxidative metabolism of dasatinib: an effective approach for determining metabolite formation kinetics. Drug Metab Dispos. 2008 Sep;36(9):1828-39. doi: 10.1124/dmd.107.020255. Epub 2008 Jun 12. [PubMed:18556438 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Trimethylamine monooxygenase activity
Specific Function:
Involved in the oxidative metabolism of a variety of xenobiotics such as drugs and pesticides. It N-oxygenates primary aliphatic alkylamines as well as secondary and tertiary amines. Plays an important role in the metabolism of trimethylamine (TMA), via the production of TMA N-oxide (TMAO). Is also able to perform S-oxidation when acting on sulfide compounds (PubMed:9224773).
Gene Name:
FMO3
Uniprot ID:
P31513
Molecular Weight:
60032.975 Da
References
  1. Wang L, Christopher LJ, Cui D, Li W, Iyer R, Humphreys WG, Zhang D: Identification of the human enzymes involved in the oxidative metabolism of dasatinib: an effective approach for determining metabolite formation kinetics. Drug Metab Dispos. 2008 Sep;36(9):1828-39. doi: 10.1124/dmd.107.020255. Epub 2008 Jun 12. [PubMed:18556438 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Dohse M, Scharenberg C, Shukla S, Robey RW, Volkmann T, Deeken JF, Brendel C, Ambudkar SV, Neubauer A, Bates SE: Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab Dispos. 2010 Aug;38(8):1371-80. doi: 10.1124/dmd.109.031302. Epub 2010 Apr 27. [PubMed:20423956 ]
  2. Hegedus C, Ozvegy-Laczka C, Apati A, Magocsi M, Nemet K, Orfi L, Keri G, Katona M, Takats Z, Varadi A, Szakacs G, Sarkadi B: Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol. 2009 Oct;158(4):1153-64. doi: 10.1111/j.1476-5381.2009.00383.x. Epub 2009 Sep 28. [PubMed:19785662 ]
  3. Giannoudis A, Davies A, Lucas CM, Harris RJ, Pirmohamed M, Clark RE: Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia. Blood. 2008 Oct 15;112(8):3348-54. doi: 10.1182/blood-2007-10-116236. Epub 2008 Jul 31. [PubMed:18669873 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Molecular Weight:
72313.47 Da
References
  1. Dohse M, Scharenberg C, Shukla S, Robey RW, Volkmann T, Deeken JF, Brendel C, Ambudkar SV, Neubauer A, Bates SE: Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab Dispos. 2010 Aug;38(8):1371-80. doi: 10.1124/dmd.109.031302. Epub 2010 Apr 27. [PubMed:20423956 ]
  2. Hegedus C, Ozvegy-Laczka C, Apati A, Magocsi M, Nemet K, Orfi L, Keri G, Katona M, Takats Z, Varadi A, Szakacs G, Sarkadi B: Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol. 2009 Oct;158(4):1153-64. doi: 10.1111/j.1476-5381.2009.00383.x. Epub 2009 Sep 28. [PubMed:19785662 ]
Comments
comments powered by Disqus
Drug created on May 08, 2007 18:32 / Updated on August 31, 2016 02:13